Dr. Martens trading in line with expectations despite ‘challenging’ UK market
Dr. Martens has confirmed that trading since the start of its new financial year has been in line with expectations.
In a trading update ahead of its AGM, the footwear brand said trading continues to be positive in its Americas direct-to-consumer (DTC) channel driven by full price sales, particularly in retail.
However, trading in its EMEA DTC business has been more variable, especially in the UK where the business continues to be impacted by challenging trading conditions.
Dr. Martens said its APAC business continues to drive good growth particularly in South Korea due to its well established shoes category in the country.
Subscribe to TRBLooking ahead, the company said it has healthy autumn/winter order books. While its EMEA order book is up year-on-year, the Americas order book is broadly in line year-on-year but based on a much wider product range than previously.
Dr. Martens said: “We are focused on embedding our new consumer-first Levers for Growth strategy, which we outlined at our results on 5 June and which builds on the work undertaken in FY25 to stabilise the business.
“The strategy capitalises on the clear strengths of the business today and taps into the significant new markets and profit pools that are available to us.
“It is centred on engaging more consumers, driving more product purchase occasions, curating market-right distribution and
simplifying the operating model.
“Further details on our early progress in these areas will be shared at our first half results in November.”
